

Recombinant Ebolavirus Glycoprotein minus the Transmembrane Region (EBOV rGPdTM)

Catalog #: 0501-001

Lot #: 1506001

Description: Mature, recombinant, HA-tagged Ebolavirus Glycoprotein minus the transmembrane domain (EBOV rGPdTM) is supplied as purified protein. EBOV rGPdTM is produced in mammalian cells and is purified by FPLC.

Storage: 2-3 weeks at -20°C, -80°C long term


Size: 100 µg of protein is supplied in PBS at a concentration of **1.008 mg/mL**. The theoretical molecular weight of the protein is ~80-120 kDa including the HA-tag, without glycosylation. Because of the highly glycosylated nature of this protein, migration in an SDS-PAGE gel is slowed resulting in broad, diffuse bands representing differing glycosylation forms.

Relevance: Recombinant glycoprotein provides a means for antibody development, control protein for testing, and a tool to enhance research.

Western Blot: Quality control testing demonstrates strong detection of GP null under reduced conditions down to 50 ng when using IBT's monoclonal antibody 4F3 (cat 0201-020) at 0.5 µg/mL.

Related Products: IBT provides a wide array of anti-filovirus specific antibodies and other infectious disease reagents. Please see our website, www.ibtbioservices.com for more details.

SDS-PAGE & Western Blot Detection



(A) SDS-PAGE and stain demonstrating 1 µg, 5 µg (lane 1, 2 respectively) of EBOV rGPdTM HA-Tag protein under denaturing and reducing conditions. MW denotes Novex Sharp prestained protein markers. (B) Western blot detection of EBOV rGPdTM at 500 ng, 100 ng, and 50 ng (lanes 1-3). EBOV rGPdTM was detected using IBT's monoclonal antibody 4F3 at 0.5 µg/mL and anti-mouse IgG-HRP conjugate, followed by TMB substrate.

ELISA Data

EBOV GPdTM ng/mL	OD 650 nm
800.00	3.701
400.00	3.580
200.00	3.527
100.00	3.629
50.00	3.533
25.00	3.321
12.50	2.844
6.25	2.089
3.13	1.339
1.56	0.733
0.78	0.430
0.39	0.256

Plate was coated with EBOV rGPdTM starting at 800 ng/well, serially diluted in DPBS. Washed plate was detected using one dilution of a positive control serum, followed with anti-IgG HRP conjugate and TMB substrate. OD₆₅₀ is reported.

Intended for research use only, not for human, therapeutic, or diagnostic applications.

The buyer cannot sell or otherwise transfer this product for Commercial Purposes without written approval of Integrated BioTherapeutics, Inc.

Copyright 2015. Integrated BioTherapeutics, Inc. All rights reserved.